title: [Complex treatment of acute hematogenous osteomyelitis in children].
abstract: The acute hematogenous osteomyelitis continues to remain at present one of the actual problems to pediatric surgery, being characterized by severe course, difficulty of the early diagnostics and frequency of unfavourable outcomes, becoming chronic and complications. We investigated the levels of CRP, IL-1beta, TNF-alpha in 74 children with acute hematogenous osteomyelitis. In the first (control) group children had standart therapy, in the second (main) group children had standart therapy with Licopid. The level of TNF-alpha in the main group on 7 days after operation was 91,8 + or - 4,1 pcg/ml, on 14 days -- 44,3 + or - 8,3 pcg/ml. The level of TNF-alpha in the control group on 14 days was 92,0 + or - 2,0 pcg/ml (p<0,01). The level of IL-1beta in the main group on 7 days -- 120,0 + or - 30,8 pcg/ml, on 14 days -- 80,0 + or - 15,3 pcg/ml. The level of IL-1beta in the control group on 14 days -- 100,5 + or - 2,4 pcg/ml. The level of CRP in the main group on 14 days -- 22,9 + or - 4,1 mg/ml. The level of CRP in the control group on 14 days -- 12,9 + or - 0,4 mg/ml (p<0,05). The use the complex treatment of acute hematogenous osteomyelitis in children has allowed to obtain a good results of the treatment.
authors.forename: S V
authors.initials: SV
authors.lastname: Minaev
authors.forename: R A
authors.initials: RA
authors.lastname: Motorina
authors.forename: V V
authors.initials: VV
authors.lastname: Leskin
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D002097:C-Reactive Protein / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003646:Debridement / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood; D008297:Male; D010019:Osteomyelitis / Q000097:blood / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000276:Adjuvants, Immunologic; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C063429:glucosaminylmuramyl-2-alanine-D-isoglutamine; D002097:C-Reactive Protein